BMS Secures ORM-6151 for Acute Myeloid Leukemia Treatment with Orum Therapeutics Deal
Bristol Myers Squibb (BMS; NYSE: BMY) has made a significant move in the field of...
Bayer Withdraws Aliqopa FDA Filing Following Missed Phase III Endpoint
Germany-based pharmaceutical major Bayer (ETR: BAYN) has announced its decision to withdraw the filing for...
Boehringer Ingelheim and Scottish Enterprise Co-Lead GBP 4.3M Seed Funding for Glox Therapeutics
Germany’s Boehringer Ingelheim, in collaboration with Scotland’s national economic development agency Scottish Enterprise, has co-led...
AnchorDx Medical Partners with DiaCarta for Global Molecular Diagnostics Development
AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing based in China, has entered...
Sisram Medical Ltd Expands Asia-Pacific Presence with New Direct Sales Office in Japan
Sisram Medical Ltd (HKG: 1696), an Israel-based company that is part of the Fosun Pharmaceutical...
Beijing-Based Immupeutics Medicine Secures Tens of Millions in Pre-Series A+ Financing
Immupeutics Medicine, a Beijing-based developer in the field of tumor immunotherapy, has reportedly secured tens...
Servier’s Tibsovo Receives FDA Approval for IDH1-Mutated R/R MDS, Expanding Indications
France-based pharmaceutical company Servier has announced that the US Food and Drug Administration (FDA) has...
Huadong Medicine’s Arcalyst (Rilonacept) Filing for CAPSs Accepted by China’s NMPA
Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that the National...
Jiangsu Hengrui Pharmaceuticals’ HR20031 Accepted for Review by China’s NMPA for Type 2 Diabetes
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading Chinese pharmaceutical company, has announced that the National...
AstraZeneca’s Imfinzi Gains NMPA Approval for First-Line Cholangiocarcinoma Treatment
The National Medical Products Administration (NMPA) of China has indicated on its website that it...
Hansoh Pharmaceutical’s HS-10511 Tablets for Hypertrophic Cardiomyopathy Cleared for Clinical Trials
Hansoh Pharmaceutical (HKG: 3692) has announced that its affiliated company’s self-developed Class 1 new drug,...
Chiesi Farmaceutici and Shanghai Pharmaceutical Partner on Distribution at CIIE
Among the series of deals secured by multinational corporations at the 6th China International Import...
Bayer Shifts Focus of Recursion Pharmaceuticals Collaboration to Precision Oncology
Germany-headquartered Bayer (ETR: BAYN) has announced a significant modification to its 2020 drug discovery collaboration...
Lizhu Pharmaceutical Cancels ChiNext IPO, Opts for NEEQ Listing for Subsidiary Lizhu Reagent
On November 11, 2023, Lizhu Pharmaceutical (HKG: 1513) announced a strategic shift in its plans...
Novo Nordisk Commits Over DKK 42 Billion to Expand Chronic Disease Production in Denmark
Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, last week announced a substantial plan to...
Eli Lilly China’s President Benjamin L. Basil to Depart for Personal Reasons
It has been reported that Benjamin L. Basil, the current president and general manager of...
Clinical Research on rAAV Gene Drug ZS805 for Fabry Disease Launched by Zhishan Weixin
Zhishan Weixin Biotechnology Co., Ltd, a China-based biotech company, has announced the launch of the...
Jiangsu Hengrui Pharmaceuticals’ Subsidiary Shengdi Pharmaceuticals Receives NMPA Approval for HRS-9057
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading pharmaceutical company in China, has announced that its...
Beijing Aosaikang’s Combo Therapy for NSCLC Accepted for Clinical Trial by NMPA
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has announced that the...
Lundbeck A/S Reports 7% YOY Revenue Increase in Q3 2023 and 9% Growth for the First Three Quarters
Denmark-based biopharmaceutical company H. Lundbeck A/S (CPH: HLUN-A) has announced its financial results for the...